(16322744), A. F. A., (16322746), W. R. K., & (16322749), M. A. Y. (2021). Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera A case report.
Chicago Style (17th ed.) Citation(16322744), Abdulrahman F. Al-Mashdali, Waail R. Kashgary (16322746), and Mohamed A. Yassin (16322749). Ruxolitinib (a JAK2 Inhibitor) as an Emerging Therapy for Refractory Pruritis in a Patient with Low-risk Polycythemia Vera A Case Report. 2021.
MLA (9th ed.) Citation(16322744), Abdulrahman F. Al-Mashdali, et al. Ruxolitinib (a JAK2 Inhibitor) as an Emerging Therapy for Refractory Pruritis in a Patient with Low-risk Polycythemia Vera A Case Report. 2021.
Warning: These citations may not always be 100% accurate.